FG-CoALS // Franco-German cohort study to determine factors associated with weight loss in amyotrophic lateral sclerosis ALS Recruiting
ReALiSe // A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants with Amyotrophic Lateral Sclerosis SLAPhase 2a Follow-Up (recruiting ended)
ASTRALS // A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis Phase 2ALS Follow-Up (recruiting ended)
SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. ALSPhase 2 Follow-Up (recruiting ended)
ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes ALSMicrobiota Coming soon
ATLAS // A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation Phase 3Individuals with ALS risk mutations Follow-Up (recruiting ended)
CARDINALS // Study to Assess the Effects of PTC857 Treatment in Participants With ALS SLAPhase 2 Completed
IASO // Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With ALS SLAPhase 1b pilot trial Completed
